Trending

liver disease

Q&A: Novartis’ Eric Hughes on transplantation

Q&A: Novartis’ Eric Hughes on transplantation

With approximately 3.2 million people worldwide living with end-stage renal disease, there is immense pressure on healthcare systems

X

Q&A: Novartis’ Eric Hughes on transplantation

https://pharmaphorum.com/r-d/views-analysis-r-d/novartis-eric-hughes-transplantation/

Conatus axes staff after latest failure of Novartis-partnered NASH drug

Conatus axes staff after latest failure of Novartis-partnered NASH drug

Conatus has said it will have to cut around 40% of its workforce and jettison some pipeline projects

X

Conatus axes staff after latest failure of Novartis-partnered NASH drug

https://pharmaphorum.com/news/conatus-axes-staff-after-latest-nash-trial-failure/

Gilead NASH drug fails late stage trial

Gilead NASH drug fails late stage trial

Gilead’s top late-stage drug selonsertib, for patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), has failed a

X

Gilead NASH drug fails late stage trial

https://pharmaphorum.com/news/gilead-nash-drug-fails-late-stage-trial/

Promethera looks to Asia with €10m investment

Promethera looks to Asia with €10m investment

Belgium-based liver disease specialists Promethera Biosciences have received a leg-up for the Asian market in the form of

X

Promethera looks to Asia with €10m investment

https://pharmaphorum.com/news/promethera-looks-to-asia-with-e10m-investment/

Novartis muscles into NASH fatty liver disease

Novartis muscles into NASH fatty liver disease

Company’s Eric Hughes on what it takes to be leader in NASH – and what can be learnt from hepatitis C.

X

Novartis muscles into NASH fatty liver disease

https://pharmaphorum.com/views-and-analysis/novartis-muscles-nash-fatty-liver-disease/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com